(Q46731853)

24 December 2017

title

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions (English)

1 reference

24 December 2017

author

Terrence F. Blaschke

3

1 reference

24 December 2017

author name string

Motoya T

1

1 reference

24 December 2017

Thevanayagam LN

2

1 reference

24 December 2017

Au S

4

1 reference

24 December 2017

Stone JA

5

1 reference

24 December 2017

Jayewardene AL

6

1 reference

24 December 2017

Chi J

7

1 reference

24 December 2017

Aweeka FT

8

1 reference

24 December 2017

publication date

1 March 2006

1 reference

24 December 2017

published in

HIV Medicine

1 reference

24 December 2017

volume

7

1 reference

24 December 2017

issue

2

1 reference

24 December 2017

page(s)

122-128

1 reference

24 December 2017

Nelfinavir mesylate: a protease inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00356.X

10.1111/J.1468-1293.2006.00356.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017